CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
Ropivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02154763
NCT02154763Phase 3Completed

A Pilot Study to Assess the Feasibility of a Future Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Role of Intra-Peritoneal Ropivacaine in Gastric Bypass Surgery: INOPAIN Trial

Ottawa Hospital Research Institute·interventional·Posted Jun 3, 2014·Updated Mar 19, 2019

In Brief

A Phase 3 clinical trial evaluating Ropivacaine and Normal Saline for Bariatric Surgery Candidate. Completed, enrolled 120 participants across 1 site.

Detailed Summary

This is a pilot study in a randomized, controlled, double-blinded format and will evaluate the ability of a local anesthetic, Ropivacaine, to decrease pain after gastric bypass surgery. The drug will be administered into the abdomen during a bariatric bypass surgery. After surgery, patients who received Ropivacaine will be compared to those without Ropivacaine to determine its effect on reducing pain, recovery of lung function, ability to walk, and quality of life during recovery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 3, 2014
Enrollment StartJul 1, 2014
Primary CompletionJan 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.1 years ago

Interventions

Ropivacainedrug

Normal Salinedrug